The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Research works printed but not linked: 33
- Brenner, 1982, Dietary protein intake and the progressive nature of kidney disease: the role of haemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis, N Engl J Med, 307, 652, 10.1056/NEJM198209093071104 · DOI · Paper page
- Hostetter, 1981, Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation, Am J Physiol, 241, F85
- Anderson, 1985, Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass, J Clin Invest, 76, 612, 10.1172/JCI112013 · DOI · Paper page
- Anderson, 1986, Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat, J Clin Invest, 77, 1993, 10.1172/JCI112528 · DOI · Paper page
- Mogensen, 1982, Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy, BMJ, 285, 685, 10.1136/bmj.285.6343.685 · DOI · Paper page
- Parving, 1983, Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy, Lancet, i, 1175, 10.1016/S0140-6736(83)92462-5 · DOI · Paper page
- Bjorck, 1992, Renal protective effect of enalapril in diabetic nephropathy, BMJ, 304, 339, 10.1136/bmj.304.6823.339 · DOI · Paper page
- Parving, 1988, Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy, BMJ, 297, 1086, 10.1136/bmj.297.6656.1086 · DOI · Paper page
- Kasiske, 1993, Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis, Ann Intern Med, 118, 129, 10.7326/0003-4819-118-2-199301150-00009 · DOI · Paper page
- Weidmann, 1995, Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis, Nephrol Dial Transplant, 10, 39
- Morelli, 1990, Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy, Diabetes, 39, 76, 10.2337/diacare.39.1.76 · DOI
- Remuzzi, 1993, Effect of low-dose enalapril on glomerular size selectivity in human diabetic nephropathy, J Nephrol, 6, 36
- Remuzzi, 1990, Angiotensin converting-enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat, J Clin Invest, 85, 541, 10.1172/JCI114470 · DOI · Paper page
- Remuzzi, 1995, Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury, Curr Opin Nephrol Hypertens, 4, 339, 10.1097/00041552-199507000-00009 · DOI
- Remuzzi, 1990, Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?, Kidney Int, 38, 384, 10.1038/ki.1990.217 · DOI · Paper page
- Bertani, 1986, Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy, Kidney Int, 30, 488, 10.1038/ki.1986.212 · DOI
- Hirschberg, 1996, Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions, J Clin Invest, 98, 116, 10.1172/JCI118755 · DOI
- Eddy, 1994, Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions, J Am Soc Nephrol, 5, 1273, 10.1681/ASN.V561273 · DOI
- Kamper, 1992, Effect of enalapril on the progression of chronic renal failure: a randomised controlled trial, Am J Hypertens, 5, 423, 10.1093/ajh/5.7.423 · DOI
- Ihle, 1996, Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double blind trial, Am J Kidney Dis, 27, 489, 10.1016/S0272-6386(96)90158-4 · DOI
- Hannedouche, 1994, Randomized controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure, BMJ, 309, 833, 10.1136/bmj.309.6958.833 · DOI
- Zucchelli, 1992, Long-term comparison between captopril and nifedipine in the progression of chronic renal insufficiency, Kidney Int, 42, 452, 10.1038/ki.1992.309 · DOI · Paper page
- Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 · DOI · Paper page
- 1991, A long-term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies, J Nephrol, 3, 193
- Haybittle, 1971, Repeated assessments of results in clinical trials of cancer treatment, Br J Radiol, 44, 793, 10.1259/0007-1285-44-526-793 · DOI · Paper page
- Erman, 1991, Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man, J Hypertens, 9, 1057, 10.1097/00004872-199111000-00012 · DOI
- Gaspari, 1995, Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate in patients with normal or impaired renal function, J Am Soc Nephrol, 6, 1, 10.1681/ASN.V62257 · DOI · Paper page
- Rice, 1975, Improved biuret procedure for determination of urinary total proteins in clinical proteinuria, Clin Chem, 21, 398, 10.1093/clinchem/21.3.398 · DOI
- Parving, 1987, Effect of antihypertensive treatment on kidney function in diabetic nephropathy, BMJ, 294, 1443, 10.1136/bmj.294.6585.1443 · DOI · Paper page
- Rossing, 1994, Reduction in albuminuria predicts diminished progression in diabetic nephropathy, Kidney Int, 45, 145
- Apperloo, 1992, The initial antiproteinuric effect of antihypertensive treatment predicts the effect of treatment on long-term renal function outcome, J Am Soc Nephrol, 3, 279
- Petterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003 · DOI · Paper page
- Remuzzi, 1991, Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy, Kidney Int, 39, 1267, 10.1038/ki.1991.160 · DOI
Cited by
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Durvasula, R. V., Petermann, A. T., Hiromura, K., Blonski, M., Pippin, J., Mundel, P., Pichler, R., Griffin, S., Couser, W. G., & Shankland, S. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00362.x · Cited by 313
Coppo (2007) · doi:10.1681/asn.2006040347 · Cited by 256
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Management of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0337-0 · Cited by 214
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001276 · Cited by 206
Rovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Epidemiology of hypertensive kidney disease
Udani, S., Lazich, I., & Bakris, G. L. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.154 · Cited by 171
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101081 · Cited by 162
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Remuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B. D., de Zeeuw, D., Hille, D. A., Shahinfar, S., Carides, G. W., & Brenner, B. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000146423.71226.0c · Cited by 123
RAS inhibition in hypertension
Ibrahim, M. M. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001960 · Cited by 114
Ahuja, T. S., Freeman Jr., D., Mahnken, J. D., Agraharkar, M., Siddiqui, M., & Memon, A. (2000) · American Journal of Nephrology · doi:10.1159/000013599 · Cited by 114
Murphy, D. P., Drawz, P. E., & Foley, R. N. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018100971 · Cited by 106
Adamczak, M., Zeier, M., Dikow, R., & Ritz, E. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.28.x · Cited by 95
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0497-6 · Cited by 55
Sarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Grøn sælen, M., Katrine prøsch, L., Gudmundsdottir, H., Dyrbekk, D., Helge Hunderi, O., Arnesen, E., Paulsen, D., Skjønsberg, H., & Os, I. (2005) · Blood Pressure · doi:10.1080/08037050510008959 · Cited by 17
Metadata
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1997-06
- Volume
- 349
- Issue
- 9069
- Pages
- 1857-1863
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3156148333
- Cited by
- 1,825
- References
- 1
- FWCI
- 59.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.